Top Markets
Coin of the day
Laboratorios Farmaceuticos Rovi, S.A. Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A.

ROVI
Rang in aandelen #4452
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses... Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
Aandeelprijs
$72.12
Marktkapitalisatie
$3.69B
Verandering (1 dag)
0.50%
Verandering (1 jaar)
8.29%
Land
ES
Handel Laboratorios Farmaceuticos Rovi, S.A. (ROVI)

Categorie

Koersgeschiedenis voor Laboratorios Farmaceuticos Rovi, S.A. (ROVI)
Hoogste slotkoers: $69.94 op 2026-08-01

Laagste slotkoers: $14.57 op 2007-12-01
Koersgeschiedenis van Laboratorios Farmaceuticos Rovi, S.A. van 2007 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 7.12%
2025 9.73%
2024 4.07%
2023 62.33%
2022 -49.66%
2021 66.55%
2020 72.63%
2019 35.52%
2018 1.97%
2017 52.26%
2016 -17.47%
2015 27.82%
2014 -9.53%
2013 98.25%
2012 1.29%
2011 3.98%
2010 -43.77%
2009 35.91%
2008 -42.53%
2007 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$171.67 -
DE
$164.46 31.03%
DE
$38.23 28.07%
JP
$222.40 30.36%
CH
$20.96 14.80%
IN